+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Bullous pemphigoid Market by Drug Class, Route Of Administration, Distribution Channel, End User, Therapy Line - Global Forecast to 2030- Product Image
Bullous pemphigoid Market by Drug Class, Route Of Administration, Distribution Channel, End User, Therapy Line - Global Forecast to 2030- Product Image
Sale

Bullous pemphigoid Market by Drug Class, Route Of Administration, Distribution Channel, End User, Therapy Line - Global Forecast to 2030

  • PDF Icon

    Report

  • 185 Pages
  • May 2025
  • Region: Global
  • 360iResearch™
  • ID: 6011507
UP TO OFF until Dec 31st 2025
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Bullous pemphigoid Market grew from USD 358.38 million in 2024 to USD 379.75 million in 2025. It is expected to continue growing at a CAGR of 5.91%, reaching USD 505.98 million by 2030.

Understanding the Foundations of Bullous Pemphigoid and Market Dynamics

Bullous pemphigoid stands as a hallmark autoimmune blistering disorder predominantly affecting older adults, manifesting with tense bullae and intense pruritus that compromise patient quality of life. Over recent years, advances in immunology and therapeutic innovation have converged to reshape the clinical and commercial landscape, offering new hope while introducing complexity for stakeholders. Clinicians grapple with balancing efficacy and safety across treatment classes, payers assess long-term value amid evolving reimbursement paradigms, and manufacturers navigate regulatory rigor alongside pipeline prioritization. Against this backdrop, a precise understanding of pathophysiology, treatment patterns, and stakeholder motivations forms the bedrock for strategic planning.

This executive summary synthesizes critical developments, market drivers, regulatory influences, and actionable insights, equipping decision-makers with a holistic perspective. It underscores the interplay between clinical unmet needs and commercial viability while illuminating strategic inflection points. By delineating segmentation drivers and regional dynamics, this analysis lays the groundwork for informed investments and partnerships that can accelerate access to life-changing therapies.

Emerging Paradigm Shifts Redefining Treatment Approaches

In recent years, therapeutic innovation has redefined the bullous pemphigoid landscape, shifting emphasis toward targeted biologic modalities and personalized care pathways. Advances in anti-IgE and anti-CD20 antibodies have opened avenues to mitigate corticosteroid reliance, addressing safety concerns linked to long-term use. Concurrently, real-world evidence platforms and digital health tools have strengthened pharmacovigilance and adherence monitoring, enabling more nuanced management of chronic immunosuppression.

On the regulatory front, accelerated approval frameworks and adaptive trial designs have reduced time to market for breakthrough candidates, fostering a more dynamic pipeline. Value-based contracting pilots have emerged, compelling manufacturers to align pricing with real-world patient outcomes. Payers and providers now collaborate on outcome measures that transcend conventional clinical endpoints, reflecting a broader shift toward patient-centric value definitions. These transformative shifts compel organizations to adapt commercial models, engage in novel partnerships, and reimagine lifecycle strategies to stay ahead in a market defined by rapid clinical and policy evolution.

Assessing the Ripple Effects of US Tariff Changes in 2025

The introduction of revised United States tariff policies in 2025 has generated a ripple effect across the bullous pemphigoid supply chain, influencing the cost structure of imported active pharmaceutical ingredients and finished products. Manufacturers reliant on overseas sourcing have encountered escalated input expenses, compelling contract manufacturers to renegotiate supply agreements or absorb margin pressure. Regulatory authorities and industry groups have engaged in ongoing dialogues to mitigate disruptions, advocating for targeted exemptions on critical immunosuppressant components to preserve patient access.

Clinicians and hospital systems have reported variability in drug availability, prompting formulary committees to explore alternative sourcing strategies or adjust therapeutic protocols. In parallel, the heightened cost environment has accelerated the adoption of local manufacturing initiatives, bolstered by public-private partnerships aimed at securing domestic production capacity. Ultimately, the 2025 tariff adjustments underscore the importance of supply chain resilience, strategic inventory management, and proactive stakeholder engagement to safeguard continuity of care.

Unveiling Comprehensive Segmentation Insights Across Therapeutic Classes and Channels

A nuanced segmentation approach reveals distinct market dynamics that vary by drug class, route of administration, distribution channel, end user, and therapy line. Breaking down the market by therapeutic categories highlights biologics such as Omalizumab and Rituximab carving out significant share by offering targeted immunomodulation with favorable safety profiles, while established corticosteroids like Methylprednisolone and Prednisone remain foundational for acute management. Immunosuppressants including Azathioprine, Methotrexate, and Mycophenolate Mofetil continue to serve as critical backbone therapies, particularly in maintenance regimens that strive to balance efficacy and tolerability.

When considering how treatments are administered, intravenous infusion emerges as a setting conducive to specialist oversight and patient monitoring, whereas oral formulations support outpatient convenience and adherence in maintenance phases. Topical applications retain a vital role in localized symptom control, reducing systemic exposure and supplementing systemic therapy. Distribution channels provide further insight: hospital pharmacies drive initial treatment uptake and manage high-cost biologic infusions, online pharmacies-both B2B platforms serving institutional clients and B2C platforms catering directly to patients-enable broader access and streamlined replenishment, and retail pharmacies maintain critical last-mile connectivity for chronic prescriptions.

End users shape purchasing and utilization patterns as well: homecare settings offer patient-centered administration for those requiring consistent intravenous support outside hospital walls, hospitals-encompassing private and public institutions-serve as focal points for both acute flares and biologic roll-out, and specialty clinics, whether dermatology or outpatient, anchor long-term disease management anchored in expert care. Finally, therapy line stratification underscores first-line interventions focused on rapid disease control, second-line options that address partial responders or relapsed patients, and maintenance phases designed to sustain remission while minimizing treatment burden.

Regional Dynamics Shaping Market Opportunities across Key Territories

Regional landscapes reveal divergent challenges and opportunities shaped by healthcare infrastructure, regulatory environments, and payer models. In the Americas, established reimbursement corridors and a high prevalence of autoimmune diseases have accelerated uptake of novel biologics, though cost-containment pressures persist through prior authorizations and step therapy protocols. Innovation in digital health integration and patient support programs has enhanced adherence and real-world data collection, reinforcing market momentum.

Europe, the Middle East & Africa presents a tapestry of heterogeneous systems where centralized regulatory mechanisms coexist with fragmented reimbursement practices. In Western Europe, streamlined approval pathways and value-based reimbursement trials have bolstered early adoption, while emerging markets in the Middle East and Africa grapple with infrastructure gaps and supply chain constraints. Collaborative initiatives among governments, NGOs, and industry stakeholders have aimed to improve access by subsidizing treatment costs and expanding specialized training for dermatology professionals.

Asia-Pacific embodies rapid growth potential underpinned by expanding healthcare investment, growing patient awareness, and nascent biologics manufacturing capabilities. Regulatory authorities in key markets have piloted expedited review processes for immunomodulatory therapies, and local companies are forging partnerships with global developers to catalyze technology transfer. Despite persisting challenges related to pricing pressures and variable payer coverage, the region’s large patient pool and increasing physician expertise position it as a critical battleground for market entrants.

Strategic Profiles of Leading Industry Stakeholders

Leading stakeholders in the bullous pemphigoid space demonstrate diverse strategic priorities, from pipeline expansion to market access optimization. Biotech firms pioneering anti-CD20 and anti-IgE platforms are investing in head-to-head trials to differentiate their candidates against established standards of care. Large pharmaceutical companies with legacy corticosteroid and immunosuppressant portfolios are streamlining manufacturing operations to enhance cost efficiency and reinvigorating branded formulations through novel delivery mechanisms.

Specialty distributors and contract manufacturing organizations are deepening service offerings, integrating cold-chain logistics for biologics and developing small-scale infusion centers to support local administration. Technology vendors specializing in remote patient monitoring tools and digital adherence platforms are forging partnerships with manufacturers and payers to deliver real‐time data on treatment outcomes. At the same time, emerging players in biosimilars seek regulatory approval pathways that leverage established reference products while offering price differentiation, posing new competitive dynamics in mature markets.

Driving Strategic Impact with Tactical Recommendations

To navigate this evolving environment, industry leaders should prioritize cross-functional collaborations that align clinical development with real-world evidence generation. Early engagement with payers and regulatory bodies can de-risk market access by validating value propositions around safety and long-term outcomes. Investing in patient support ecosystems-encompassing digital adherence tools, educational resources, and infusion infrastructure-can differentiate brands and foster loyalty.

Manufacturers should diversify sourcing strategies to mitigate tariff-related disruptions, balancing global procurement with targeted local production. Developing adaptive pricing models that tie reimbursement to demonstrable patient benefit will resonate with value-conscious payers. On the commercial front, segmentation-driven outreach-tailored to hospitals, specialty clinics, and homecare providers-will optimize resource allocation and amplify brand penetration. Finally, embracing emerging technologies such as teledermatology and AI-powered diagnostics can streamline patient identification and accelerate intervention timelines.

Robust Methodological Framework Ensuring Analytical Rigor

This analysis integrates primary interviews with key opinion leaders, payers, and patients, alongside comprehensive secondary research encompassing peer-reviewed publications, regulatory filings, and proprietary databases. A multi-stage validation process ensured data integrity, with quantitative inputs corroborated through triangulation against public financial disclosures and clinical registries. Qualitative insights emerged from structured interviews with dermatology specialists, infusion center operators, and reimbursement experts across major regions.

Segmentation frameworks were developed through iterative model calibration, capturing drug class dynamics, administration routes, and distribution channel nuances. Regional analyses accounted for policy variations, healthcare infrastructure profiles, and epidemiological trends. Company assessments combined SWOT evaluations with pipeline mapping to elucidate competitive positioning. This rigorous methodology underpins the reliability and relevance of the insights presented, offering a robust foundation for strategic decision-making.

Synthesis of Core Insights and Future Industry Trajectory

The convergence of therapeutic innovation, regulatory evolution, and supply chain realignment underscores a pivotal moment in the bullous pemphigoid arena. Targeted biologics are reshaping treatment paradigms, while established therapies maintain critical roles in acute and maintenance settings. Tariff-driven cost challenges and regional disparities in access highlight the need for resilient operations and adaptive market strategies.

Segmentation and regional insights reveal that success hinges on tailored engagement models, value-based contracting, and integrated patient support systems. Companies that leverage real-world evidence, embrace digital health solutions, and foster collaborative payer relationships are best positioned to lead the next wave of innovation. As the landscape continues to evolve, stakeholders must remain agile, informed by rigorous data and aligned around patient outcomes to capture sustainable growth opportunities.

Market Segmentation & Coverage

This research report categorizes to forecast the revenues and analyze trends in each of the following sub-segmentations:
  • Drug Class
    • Biologics
      • Omalizumab
      • Rituximab
    • Corticosteroids
      • Methylprednisolone
      • Prednisone
    • Immunosuppressants
      • Azathioprine
      • Methotrexate
      • Mycophenolate Mofetil
  • Route Of Administration
    • Intravenous
    • Oral
    • Topical
  • Distribution Channel
    • Hospital Pharmacy
    • Online Pharmacy
      • B2B Platform
      • B2C Platform
    • Retail Pharmacy
  • End User
    • Homecare Settings
    • Hospitals
      • Private Hospitals
      • Public Hospitals
    • Specialty Clinics
      • Dermatology Clinics
      • Outpatient Clinics
  • Therapy Line
    • First Line
    • Maintenance
    • Second Line
This research report categorizes to forecast the revenues and analyze trends in each of the following sub-regions:
  • Americas
    • United States
      • California
      • Texas
      • New York
      • Florida
      • Illinois
      • Pennsylvania
      • Ohio
    • Canada
    • Mexico
    • Brazil
    • Argentina
  • Europe, Middle East & Africa
    • United Kingdom
    • Germany
    • France
    • Russia
    • Italy
    • Spain
    • United Arab Emirates
    • Saudi Arabia
    • South Africa
    • Denmark
    • Netherlands
    • Qatar
    • Finland
    • Sweden
    • Nigeria
    • Egypt
    • Turkey
    • Israel
    • Norway
    • Poland
    • Switzerland
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • Indonesia
    • Thailand
    • Philippines
    • Malaysia
    • Singapore
    • Vietnam
    • Taiwan
This research report categorizes to delves into recent significant developments and analyze trends in each of the following companies:
  • F. Hoffmann-La Roche AG
  • Sanofi S.A.
  • Argenx SE
  • Regeneron Pharmaceuticals, Inc.
  • GlaxoSmithKline plc
  • AstraZeneca plc
  • Novartis AG
  • AbbVie Inc.
  • Pfizer Inc.
  • Bristol-Myers Squibb Company

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Bullous pemphigoid Market, by Drug Class
8.1. Introduction
8.2. Biologics
8.2.1. Omalizumab
8.2.2. Rituximab
8.3. Corticosteroids
8.3.1. Methylprednisolone
8.3.2. Prednisone
8.4. Immunosuppressants
8.4.1. Azathioprine
8.4.2. Methotrexate
8.4.3. Mycophenolate Mofetil
9. Bullous pemphigoid Market, by Route Of Administration
9.1. Introduction
9.2. Intravenous
9.3. Oral
9.4. Topical
10. Bullous pemphigoid Market, by Distribution Channel
10.1. Introduction
10.2. Hospital Pharmacy
10.3. Online Pharmacy
10.3.1. B2B Platform
10.3.2. B2C Platform
10.4. Retail Pharmacy
11. Bullous pemphigoid Market, by End User
11.1. Introduction
11.2. Homecare Settings
11.3. Hospitals
11.3.1. Private Hospitals
11.3.2. Public Hospitals
11.4. Specialty Clinics
11.4.1. Dermatology Clinics
11.4.2. Outpatient Clinics
12. Bullous pemphigoid Market, by Therapy Line
12.1. Introduction
12.2. First Line
12.3. Maintenance
12.4. Second Line
13. Americas Bullous pemphigoid Market
13.1. Introduction
13.2. United States
13.3. Canada
13.4. Mexico
13.5. Brazil
13.6. Argentina
14. Europe, Middle East & Africa Bullous pemphigoid Market
14.1. Introduction
14.2. United Kingdom
14.3. Germany
14.4. France
14.5. Russia
14.6. Italy
14.7. Spain
14.8. United Arab Emirates
14.9. Saudi Arabia
14.10. South Africa
14.11. Denmark
14.12. Netherlands
14.13. Qatar
14.14. Finland
14.15. Sweden
14.16. Nigeria
14.17. Egypt
14.18. Turkey
14.19. Israel
14.20. Norway
14.21. Poland
14.22. Switzerland
15. Asia-Pacific Bullous pemphigoid Market
15.1. Introduction
15.2. China
15.3. India
15.4. Japan
15.5. Australia
15.6. South Korea
15.7. Indonesia
15.8. Thailand
15.9. Philippines
15.10. Malaysia
15.11. Singapore
15.12. Vietnam
15.13. Taiwan
16. Competitive Landscape
16.1. Market Share Analysis, 2024
16.2. FPNV Positioning Matrix, 2024
16.3. Competitive Analysis
16.3.1. F. Hoffmann-La Roche AG
16.3.2. Sanofi S.A.
16.3.3. Argenx SE
16.3.4. Regeneron Pharmaceuticals, Inc.
16.3.5. GlaxoSmithKline plc
16.3.6. AstraZeneca plc
16.3.7. Novartis AG
16.3.8. AbbVie Inc.
16.3.9. Pfizer Inc.
16.3.10. Bristol-Myers Squibb Company
17. ResearchAI
18. ResearchStatistics
19. ResearchContacts
20. ResearchArticles
21. Appendix
List of Figures
FIGURE 1. BULLOUS PEMPHIGOID MARKET MULTI-CURRENCY
FIGURE 2. BULLOUS PEMPHIGOID MARKET MULTI-LANGUAGE
FIGURE 3. BULLOUS PEMPHIGOID MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL BULLOUS PEMPHIGOID MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL BULLOUS PEMPHIGOID MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL BULLOUS PEMPHIGOID MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL BULLOUS PEMPHIGOID MARKET SIZE, BY DRUG CLASS, 2024 VS 2030 (%)
FIGURE 8. GLOBAL BULLOUS PEMPHIGOID MARKET SIZE, BY DRUG CLASS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL BULLOUS PEMPHIGOID MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2030 (%)
FIGURE 10. GLOBAL BULLOUS PEMPHIGOID MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL BULLOUS PEMPHIGOID MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 12. GLOBAL BULLOUS PEMPHIGOID MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL BULLOUS PEMPHIGOID MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 14. GLOBAL BULLOUS PEMPHIGOID MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL BULLOUS PEMPHIGOID MARKET SIZE, BY THERAPY LINE, 2024 VS 2030 (%)
FIGURE 16. GLOBAL BULLOUS PEMPHIGOID MARKET SIZE, BY THERAPY LINE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. AMERICAS BULLOUS PEMPHIGOID MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 18. AMERICAS BULLOUS PEMPHIGOID MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. UNITED STATES BULLOUS PEMPHIGOID MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 20. UNITED STATES BULLOUS PEMPHIGOID MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. EUROPE, MIDDLE EAST & AFRICA BULLOUS PEMPHIGOID MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. EUROPE, MIDDLE EAST & AFRICA BULLOUS PEMPHIGOID MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. ASIA-PACIFIC BULLOUS PEMPHIGOID MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 24. ASIA-PACIFIC BULLOUS PEMPHIGOID MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. BULLOUS PEMPHIGOID MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 26. BULLOUS PEMPHIGOID MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. BULLOUS PEMPHIGOID MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL BULLOUS PEMPHIGOID MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL BULLOUS PEMPHIGOID MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL BULLOUS PEMPHIGOID MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL BULLOUS PEMPHIGOID MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL BULLOUS PEMPHIGOID MARKET SIZE, BY BIOLOGICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL BULLOUS PEMPHIGOID MARKET SIZE, BY OMALIZUMAB, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL BULLOUS PEMPHIGOID MARKET SIZE, BY RITUXIMAB, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL BULLOUS PEMPHIGOID MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL BULLOUS PEMPHIGOID MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL BULLOUS PEMPHIGOID MARKET SIZE, BY METHYLPREDNISOLONE, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL BULLOUS PEMPHIGOID MARKET SIZE, BY PREDNISONE, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL BULLOUS PEMPHIGOID MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL BULLOUS PEMPHIGOID MARKET SIZE, BY IMMUNOSUPPRESSANTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL BULLOUS PEMPHIGOID MARKET SIZE, BY AZATHIOPRINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL BULLOUS PEMPHIGOID MARKET SIZE, BY METHOTREXATE, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL BULLOUS PEMPHIGOID MARKET SIZE, BY MYCOPHENOLATE MOFETIL, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL BULLOUS PEMPHIGOID MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL BULLOUS PEMPHIGOID MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL BULLOUS PEMPHIGOID MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL BULLOUS PEMPHIGOID MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL BULLOUS PEMPHIGOID MARKET SIZE, BY TOPICAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL BULLOUS PEMPHIGOID MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL BULLOUS PEMPHIGOID MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL BULLOUS PEMPHIGOID MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL BULLOUS PEMPHIGOID MARKET SIZE, BY B2B PLATFORM, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL BULLOUS PEMPHIGOID MARKET SIZE, BY B2C PLATFORM, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL BULLOUS PEMPHIGOID MARKET SIZE, BY ONLINE PHARMACY, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL BULLOUS PEMPHIGOID MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL BULLOUS PEMPHIGOID MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL BULLOUS PEMPHIGOID MARKET SIZE, BY HOMECARE SETTINGS, BY REGION, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL BULLOUS PEMPHIGOID MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL BULLOUS PEMPHIGOID MARKET SIZE, BY PRIVATE HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL BULLOUS PEMPHIGOID MARKET SIZE, BY PUBLIC HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL BULLOUS PEMPHIGOID MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL BULLOUS PEMPHIGOID MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL BULLOUS PEMPHIGOID MARKET SIZE, BY DERMATOLOGY CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL BULLOUS PEMPHIGOID MARKET SIZE, BY OUTPATIENT CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 40. GLOBAL BULLOUS PEMPHIGOID MARKET SIZE, BY SPECIALTY CLINICS, 2018-2030 (USD MILLION)
TABLE 41. GLOBAL BULLOUS PEMPHIGOID MARKET SIZE, BY THERAPY LINE, 2018-2030 (USD MILLION)
TABLE 42. GLOBAL BULLOUS PEMPHIGOID MARKET SIZE, BY FIRST LINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 43. GLOBAL BULLOUS PEMPHIGOID MARKET SIZE, BY MAINTENANCE, BY REGION, 2018-2030 (USD MILLION)
TABLE 44. GLOBAL BULLOUS PEMPHIGOID MARKET SIZE, BY SECOND LINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 45. AMERICAS BULLOUS PEMPHIGOID MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 46. AMERICAS BULLOUS PEMPHIGOID MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 47. AMERICAS BULLOUS PEMPHIGOID MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 48. AMERICAS BULLOUS PEMPHIGOID MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
TABLE 49. AMERICAS BULLOUS PEMPHIGOID MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 50. AMERICAS BULLOUS PEMPHIGOID MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 51. AMERICAS BULLOUS PEMPHIGOID MARKET SIZE, BY ONLINE PHARMACY, 2018-2030 (USD MILLION)
TABLE 52. AMERICAS BULLOUS PEMPHIGOID MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 53. AMERICAS BULLOUS PEMPHIGOID MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 54. AMERICAS BULLOUS PEMPHIGOID MARKET SIZE, BY SPECIALTY CLINICS, 2018-2030 (USD MILLION)
TABLE 55. AMERICAS BULLOUS PEMPHIGOID MARKET SIZE, BY THERAPY LINE, 2018-2030 (USD MILLION)
TABLE 56. AMERICAS BULLOUS PEMPHIGOID MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 57. UNITED STATES BULLOUS PEMPHIGOID MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 58. UNITED STATES BULLOUS PEMPHIGOID MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 59. UNITED STATES BULLOUS PEMPHIGOID MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 60. UNITED STATES BULLOUS PEMPHIGOID MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
TABLE 61. UNITED STATES BULLOUS PEMPHIGOID MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 62. UNITED STATES BULLOUS PEMPHIGOID MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 63. UNITED STATES BULLOUS PEMPHIGOID MARKET SIZE, BY ONLINE PHARMACY, 2018-2030 (USD MILLION)
TABLE 64. UNITED STATES BULLOUS PEMPHIGOID MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 65. UNITED STATES BULLOUS PEMPHIGOID MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 66. UNITED STATES BULLOUS PEMPHIGOID MARKET SIZE, BY SPECIALTY CLINICS, 2018-2030 (USD MILLION)
TABLE 67. UNITED STATES BULLOUS PEMPHIGOID MARKET SIZE, BY THERAPY LINE, 2018-2030 (USD MILLION)
TABLE 68. UNITED STATES BULLOUS PEMPHIGOID MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 69. CANADA BULLOUS PEMPHIGOID MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 70. CANADA BULLOUS PEMPHIGOID MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 71. CANADA BULLOUS PEMPHIGOID MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 72. CANADA BULLOUS PEMPHIGOID MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
TABLE 73. CANADA BULLOUS PEMPHIGOID MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 74. CANADA BULLOUS PEMPHIGOID MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 75. CANADA BULLOUS PEMPHIGOID MARKET SIZE, BY ONLINE PHARMACY, 2018-2030 (USD MILLION)
TABLE 76. CANADA BULLOUS PEMPHIGOID MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 77. CANADA BULLOUS PEMPHIGOID MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 78. CANADA BULLOUS PEMPHIGOID MARKET SIZE, BY SPECIALTY CLINICS, 2018-2030 (USD MILLION)
TABLE 79. CANADA BULLOUS PEMPHIGOID MARKET SIZE, BY THERAPY LINE, 2018-2030 (USD MILLION)
TABLE 80. MEXICO BULLOUS PEMPHIGOID MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 81. MEXICO BULLOUS PEMPHIGOID MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 82. MEXICO BULLOUS PEMPHIGOID MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 83. MEXICO BULLOUS PEMPHIGOID MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
TABLE 84. MEXICO BULLOUS PEMPHIGOID MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 85. MEXICO BULLOUS PEMPHIGOID MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 86. MEXICO BULLOUS PEMPHIGOID MARKET SIZE, BY ONLINE PHARMACY, 2018-2030 (USD MILLION)
TABLE 87. MEXICO BULLOUS PEMPHIGOID MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 88. MEXICO BULLOUS PEMPHIGOID MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 89. MEXICO BULLOUS PEMPHIGOID MARKET SIZE, BY SPECIALTY CLINICS, 2018-2030 (USD MILLION)
TABLE 90. MEXICO BULLOUS PEMPHIGOID MARKET SIZE, BY THERAPY LINE, 2018-2030 (USD MILLION)
TABLE 91. BRAZIL BULLOUS PEMPHIGOID MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 92. BRAZIL BULLOUS PEMPHIGOID MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 93. BRAZIL BULLOUS PEMPHIGOID MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 94. BRAZIL BULLOUS PEMPHIGOID MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
TABLE 95. BRAZIL BULLOUS PEMPHIGOID MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 96. BRAZIL BULLOUS PEMPHIGOID MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 97. BRAZIL BULLOUS PEMPHIGOID MARKET SIZE, BY ONLINE PHARMACY, 2018-2030 (USD MILLION)
TABLE 98. BRAZIL BULLOUS PEMPHIGOID MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 99. BRAZIL BULLOUS PEMPHIGOID MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 100. BRAZIL BULLOUS PEMPHIGOID MARKET SIZE, BY SPECIALTY CLINICS, 2018-2030 (USD MILLION)
TABLE 101. BRAZIL BULLOUS PEMPHIGOID MARKET SIZE, BY THERAPY LINE, 2018-2030 (USD MILLION)
TABLE 102. ARGENTINA BULLOUS PEMPHIGOID MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 103. ARGENTINA BULLOUS PEMPHIGOID MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 104. ARGENTINA BULLOUS PEMPHIGOID MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 105. ARGENTINA BULLOUS PEMPHIGOID MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
TABLE 106. ARGENTINA BULLOUS PEMPHIGOID MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 107. ARGENTINA BULLOUS PEMPHIGOID MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 108. ARGENTINA BULLOUS PEMPHIGOID MARKET SIZE, BY ONLINE PHARMACY, 2018-2030 (USD MILLION)
TABLE 109. ARGENTINA BULLOUS PEMPHIGOID MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 110. ARGENTINA BULLOUS PEMPHIGOID MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 111. ARGENTINA BULLOUS PEMPHIGOID MARKET SIZE, BY SPECIALTY CLINICS, 2018-2030 (USD MILLION)
TABLE 112. ARGENTINA BULLOUS PEMPHIGOID MARKET SIZE, BY THERAPY LINE, 2018-2030 (USD MILLION)
TABLE 113. EUROPE, MIDDLE EAST & AFRICA BULLOUS PEMPHIGOID MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 114. EUROPE, MIDDLE EAST & AFRICA BULLOUS PEMPHIGOID MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 115. EUROPE, MIDDLE EAST & AFRICA BULLOUS PEMPHIGOID MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 116. EUROPE, MIDDLE EAST & AFRICA BULLOUS PEMPHIGOID MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
TABLE 117. EUROPE, MIDDLE EAST & AFRICA BULLOUS PEMPHIGOID MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 118. EUROPE, MIDDLE EAST & AFRICA BULLOUS PEMPHIGOID MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 119. EUROPE, MIDDLE EAST & AFRICA BULLOUS PEMPHIGOID MARKET SIZE, BY ONLINE PHARMACY, 2018-2030 (USD MILLION)
TABLE 120. EUROPE, MIDDLE EAST & AFRICA BULLOUS PEMPHIGOID MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 121. EUROPE, MIDDLE EAST & AFRICA BULLOUS PEMPHIGOID MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 122. EUROPE, MIDDLE EAST & AFRICA BULLOUS PEMPHIGOID MARKET SIZE, BY SPECIALTY CLINICS, 2018-2030 (USD MILLION)
TABLE 123. EUROPE, MIDDLE EAST & AFRICA BULLOUS PEMPHIGOID MARKET SIZE, BY THERAPY LINE, 2018-2030 (USD MILLION)
TABLE 124. EUROPE, MIDDLE EAST & AFRICA BULLOUS PEMPHIGOID MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 125. UNITED KINGDOM BULLOUS PEMPHIGOID MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 126. UNITED KINGDOM BULLOUS PEMPHIGOID MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 127. UNITED KINGDOM BULLOUS PEMPHIGOID MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 128. UNITED KINGDOM BULLOUS PEMPHIGOID MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
TABLE 129. UNITED KINGDOM BULLOUS PEMPHIGOID MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 130. UNITED KINGDOM BULLOUS PEMPHIGOID MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 131. UNITED KINGDOM BULLOUS PEMPHIGOID MARKET SIZE, BY ONLINE PHARMACY, 2018-2030 (USD MILLION)
TABLE 132. UNITED KINGDOM BULLOUS PEMPHIGOID MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 133. UNITED KINGDOM BULLOUS PEMPHIGOID MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 134. UNITED KINGDOM BULLOUS PEMPHIGOID MARKET SIZE, BY SPECIALTY CLINICS, 2018-2030 (USD MILLION)
TABLE 135. UNITED KINGDOM BULLOUS PEMPHIGOID MARKET SIZE, BY THERAPY LINE, 2018-2030 (USD MILLION)
TABLE 136. GERMANY BULLOUS PEMPHIGOID MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 137. GERMANY BULLOUS PEMPHIGOID MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 138. GERMANY BULLOUS PEMPHIGOID MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 139. GERMANY BULLOUS PEMPHIGOID MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
TABLE 140. GERMANY BULLOUS PEMPHIGOID MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 141. GERMANY BULLOUS PEMPHIGOID MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 142. GERMANY BULLOUS PEMPHIGOID MARKET SIZE, BY ONLINE PHARMACY, 2018-2030 (USD MILLION)
TABLE 143. GERMANY BULLOUS PEMPHIGOID MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 144. GERMANY BULLOUS PEMPHIGOID MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 145. GERMANY BULLOUS PEMPHIGOID MARKET SIZE, BY SPECIALTY CLINICS, 2018-2030 (USD MILLION)
TABLE 146. GERMANY BULLOUS PEMPHIGOID MARKET SIZE, BY THERAPY LINE, 2018-2030 (USD MILLION)
TABLE 147. FRANCE BULLOUS PEMPHIGOID MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 148. FRANCE BULLOUS PEMPHIGOID MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 149. FRANCE BULLOUS PEMPHIGOID MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 150. FRANCE BULLOUS PEMPHIGOID MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
TABLE 151. FRANCE BULLOUS PEMPHIGOID MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 152. FRANCE BULLOUS PEMPHIGOID MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 153. FRANCE BULLOUS PEMPHIGOID MARKET SIZE, BY ONLINE PHARMACY, 2018-2030 (USD MILLION)
TABLE 154. FRANCE BULLOUS PEMPHIGOID MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 155. FRANCE BULLOUS PEMPHIGOID MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 156. FRANCE BULLOUS PEMPHIGOID MARKET SIZE, BY SPECIALTY CLINICS, 2018-2030 (USD MILLION)
TABLE 157. FRANCE BULLOUS PEMPHIGOID MARKET SIZE, BY THERAPY LINE, 2018-2030 (USD MILLION)
TABLE 158. RUSSIA BULLOUS PEMPHIGOID MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 159. RUSSIA BULLOUS PEMPHIGOID MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 160. RUSSIA BULLOUS PEMPHIGOID MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 161. RUSSIA BULLOUS PEMPHIGOID MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
TABLE 162. RUSSIA BULLOUS PEMPHIGOID MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 163. RUSSIA BULLOUS PEMPHIGOID MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 164. RUSSIA BULLOUS PEMPHIGOID MARKET SIZE, BY ONLINE PHARMACY, 2018-2030 (USD MILLION)
TABLE 165. RUSSIA BULLOUS PEMPHIGOID MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 166. RUSSIA BULLOUS PEMPHIGOID MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 167. RUSSIA BULLOUS PEMPHIGOID MARKET SIZE, BY SPECIALTY CLINICS, 2018-2030 (USD MILLION)
TABLE 168. RUSSIA BULLOUS PEMPHIGOID MARKET SIZE, BY THERAPY LINE, 2018-2030 (USD MILLION)
TABLE 169. ITALY BULLOUS PEMPHIGOID MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 170. ITALY BULLOUS PEMPHIGOID MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 171. ITALY BULLOUS PEMPHIGOID MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 172. ITALY BULLOUS PEMPHIGOID MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
TABLE 173. ITALY BULLOUS PEMPHIGOID MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 174. ITALY BULLOUS PEMPHIGOID MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 175. ITALY BULLOUS PEMPHIGOID MARKET SIZE, BY ONLINE PHARMACY, 2018-2030 (USD MILLION)
TABLE 176. ITALY BULLOUS PEMPHIGOID MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 177. ITALY BULLOUS PEMPHIGOID MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 178. ITALY BULLOUS PEMPHIGOID MARKET SIZE, BY SPECIALTY CLINICS, 2018-2030 (USD MILLION)
TABLE 179. ITALY BULLOUS PEMPHIGOID MARKET SIZE, BY THERAPY LINE, 2018-2030 (USD MILLION)
TABLE 180. SPAIN BULLOUS PEMPHIGOID MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 181. SPAIN BULLOUS PEMPHIGOID MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 182. SPAIN BULLOUS PEMPHIGOID MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 183. SPAIN BULLOUS PEMPHIGOID MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
TABLE 184. SPAIN BULLOUS PEMPHIGOID MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 185. SPAIN BULLOUS PEMPHIGOID MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 186. SPAIN BULLOUS PEMPHIGOID MARKET SIZE, BY ONLINE PHARMACY, 2018-2030 (USD MILLION)
TABLE 187. SPAIN BULLOUS PEMPHIGOID MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 188. SPAIN BULLOUS PEMPHIGOID MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 189. SPAIN BULLOUS PEMPHIGOID MARKET SIZE, BY SPECIALTY CLINICS, 2018-2030 (USD MILLION)
TABLE 190. SPAIN BULLOUS PEMPHIGOID MARKET SIZE, BY THERAPY LINE, 2018-2030 (USD MILLION)
TABLE 191. UNITED ARAB EMIRATES BULLOUS PEMPHIGOID MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 192. UNITED ARAB EMIRATES BULLOUS PEMPHIGOID MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 193. UNITED ARAB EMIRATES BULLOUS PEMPHIGOID MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 194. UNITED ARAB EMIRATES BULLOUS PEMPHIGOID MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
TABLE 195. UNITED ARAB EMIRATES BULLOUS PEMPHIGOID MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 196. UNITED ARAB EMIRATES BULLOUS PEMPHIGOID MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 197. UNITED ARAB EMIRATES BULLOUS PEMPHIGOID MARKET SIZE, BY ONLINE PHARMACY, 2018-2030 (USD MILLION)
TABLE 198. UNITED ARAB EMIRATES BULLOUS PEMPHIGOID MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 199. UNITED ARAB EMIRATES BULLOUS PEMPHIGOID MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 200. UNITED ARAB EMIRATES BULLOUS PEMPHIGOID MARKET SIZE, BY SPECIALTY CLINICS, 2018-2030 (USD MILLION)
TABLE 201. UNITED ARAB EMIRATES BULLOUS PEMPHIGOID MARKET SIZE, BY THERAPY LINE, 2018-2030 (USD MILLION)
TABLE 202. SAUDI ARABIA BULLOUS PEMPHIGOID MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 203. SAUDI ARABIA BULLOUS PEMPHIGOID MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 204. SAUDI ARABIA BULLOUS PEMPHIGOID MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 205. SAUDI ARABIA BULLOUS PEMPHIGOID MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
TABLE 206. SAUDI ARABIA BULLOUS PEMPHIGOID MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 207. SAUDI ARABIA BULLOUS PEMPHIGOID MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 208. SAUDI ARABIA BULLOUS PEMPHIGOID MARKET SIZE, BY ONLINE PHARMACY, 2018-2030 (USD MILLION)
TABLE 209. SAUDI ARABIA BULLOUS PEMPHIGOID MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 210. SAUDI ARABIA BULLOUS PEMPHIGOID MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 211. SAUDI ARABIA BULLOUS PEMPHIGOID MARKET SIZE, BY SPECIALTY CLINICS, 2018-2030 (USD MILLION)
TABLE 212. SAUDI ARABIA BULLOUS PEMPHIGOID MARKET SIZE, BY THERAPY LINE, 2018-2030 (USD MILLION)
TABLE 213. SOUTH AFRICA BULLOUS PEMPHIGOID MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 214. SOUTH AFRICA BULLOUS PEMPHIGOID MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 215. SOUTH AFRICA BULLOUS PEMPHIGOID MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 216. SOUTH AFRICA BULLOUS PEMPHIGOID MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
TABLE 217. SOUTH AFRICA BULLOUS PEMPHIGOID MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 218. SOUTH AFRICA BULLOUS PEMPHIGOID MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 219. SOUTH AFRICA BULLOUS PEMPHIGOID MARKET SIZE, BY ONLINE PHARMACY, 2018-2030 (USD MILLION)
TABLE 220. SOUTH AFRICA BULLOUS PEMPHIGOID MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 221. SOUTH AFRICA BULLOUS PEMPHIGOID MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 222. SOUTH AFRICA BULLOUS PEMPHIGOID MARKET SIZE, BY SPECIALTY CLINICS, 2018-2030 (USD MILLION)
TABLE 223. SOUTH AFRICA BULLOUS PEMPHIGOID MARKET SIZE, BY THERAPY LINE, 2018-2030 (USD MILLION)
TABLE 224. DENMARK BULLOUS PEMPHIGOID MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 225. DENMARK BULLOUS PEMPHIGOID MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 226. DENMARK BULLOUS PEMPHIGOID MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 227. DENMARK BULLOUS PEMPHIGOID MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
TABLE 228. DENMARK BULLOUS PEMPHIGOID MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 229. DENMARK BULLOUS PEMPHIGOID MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 230. DENMARK BULLOUS PEMPHIGOID MARKET SIZE, BY ONLINE PHARMACY, 2018-2030 (USD MILLION)
TABLE 231. DENMARK BULLOUS PEMPHIGOID MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 232. DENMARK BULLOUS PEMPHIGOID MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 233. DENMARK BULLOUS PEMPHIGOID MARKET SIZE, BY SPECIALTY CLINICS, 2018-2030 (USD MILLION)
TABLE 234. DENMARK BULLOUS PEMPHIGOID MARKET SIZE, BY THERAPY LINE, 2018-2030 (USD MILLION)
TABLE 235. NETHERLANDS BULLOUS PEMPHIGOID MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 236. NETHERLANDS BULLOUS PEMPHIGOID MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 237. NETHERLANDS BULLOUS PEMPHIGOID MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 238. NETHERLANDS BULLOUS PEMPHIGOID MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
TABLE 239. NETHERLANDS BULLOUS PEMPHIGOID MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 240. NETHERLANDS BULLOUS PEMPHIGOID MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 241. NETHERLANDS BULLOUS PEMPHIGOID MARKET SIZE, BY ONLINE PHARMACY, 2018-2030 (USD MILLION)
TABLE 242. NETHERLANDS BULLOUS PEMPHIGOID MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 243. NETHERLANDS BULLOUS PEMPHIGOID MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 244. NETHERLANDS BULLOUS PEMPHIGOID MARKET SIZE, BY SPECIALTY CLINICS, 2018-2030 (USD MILLION)
TABLE 245. NETHERLANDS BULLOUS PEMPHIGOID MARKET SIZE, BY THERAPY LINE, 2018-2030 (USD MILLION)
TABLE 246. QATAR BULLOUS PEMPHIGOID MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 247. QATAR BULLOUS PEMPHIGOID MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 248. QATAR BULLOUS PEMPHIGOID MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 249. QATAR BULLOUS PEMPHIGOID MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
TABLE 250. QATAR BULLOUS PEMPHIGOID MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 251. QATAR BULLOUS PEMPHIGOID MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 252. QATAR BULLOUS PEMPHIGOID MARKET SIZE, BY ONLINE PHARMACY, 2018-2030 (USD MILLION)
TABLE 253. QATAR BULLOUS PEMPHIGOID MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 254. QATAR BULLOUS PEMPHIGOID MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 255. QATAR BULLOUS PEMPHIGOID MARKET SIZE, BY SPECIALTY CLINICS, 2018-2030 (USD MILLION)
TABLE 256. QATAR BULLOUS PEMPHIGOID MARKET SIZE, BY THERAPY LINE, 2018-2030 (USD MILLION)
TABLE 257. FINLAND BULLOUS PEMPHIGOID MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 258. FINLAND BULLOUS PEMPHIGOID MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 259. FINLAND BULLOUS PEMPHIGOID MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 260. FINLAND BULLOUS PEMPHIGOID MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
TABLE 261. FINLAND BULLOUS PEMPHIGOID MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 262. FINLAND BULLOUS PEMPHIGOID MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 263. FINLAND BULLOUS PEMPHIGOID MARKET SIZE, BY ONLINE PHARMACY, 2018-2030 (USD MILLION)
TABLE 264. FINLAND BULLOUS PEMPHIGOID MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 265. FINLAND BULLOUS PEMPHIGOID MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 266. FINLAND BULLOUS PEMPHIGOID MARKET SIZE, BY SPECIALTY CLINICS, 2018-2030 (USD MILLION)
TABLE 267. FINLAND BULLOUS PEMPHIGOID MARKET SIZE, BY THERAPY LINE, 2018-2030 (USD MILLION)
TABLE 268. SWEDEN BULLOUS PEMPHIGOID MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 269. SWEDEN BULLOUS PEMPHIGOID MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 270. SWEDEN BULLOUS PEMPHIGOID MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 271. SWEDEN BULLOUS PEMPHIGOID MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
TABLE 272. SWEDEN BULLOUS PEMPHIGOID MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 273. SWEDEN BULLOUS PEMPHIGOID MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 274. SWEDEN BULLOUS PEMPHIGOID MARKET SIZE, BY ONLINE PHARMACY, 2018-2030 (USD MILLION)
TABLE 275. SWEDEN BULLOUS PEMPHIGOID MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 276. SWEDEN BULLOUS PEMPHIGOID MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 277. SWEDEN BULLOUS PEMPHIGOID MARKET SIZE, BY SPECIALTY CLINICS, 2018-2030 (USD MILLION)
TABLE 278. SWEDEN BULLOUS PEMPHIGOID MARKET SIZE, BY THERAPY LINE, 2018-2030 (USD MILLION)
TABLE 279. NIGERIA BULLOUS PEMPHIGOID MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 280. NIGERIA BULLOUS PEMPHIGOID MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 281. NIGERIA BULLOUS PEMPHIGOID MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 282. NIGERIA BULLOUS PEMPHIGOID MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
TABLE 283. NIGERIA BULLOUS PEMPHIGOID MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 284. NIGERIA BULLOUS PEMPHIGOID MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 285. NIGERIA BULLOUS PEMPHIGOID MARKET SIZE, BY ONLINE PHARMACY, 2018-2030 (USD MILLION)
TABLE 286. NIGERIA BULLOUS PEMPHIGOID MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 287. NIGERIA BULLOUS PEMPHIGOID MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 288. NIGERIA BULLOUS PEMPHIGOID MARKET SIZE, BY SPECIALTY CLINICS, 2018-2030 (USD MILLION)
TABLE 289. NIGERIA BULLOUS PEMPHIGOID MARKET SIZE, BY THERAPY LINE, 2018-2030 (USD MILLION)
TABLE 290. EGYPT BULLOUS PEMPHIGOID MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 291. EGYPT BULLOUS PEMPHIGOID MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 292. EGYPT BULLOUS PEMPHIGOID MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 293. EGYPT BULLOUS PEMPHIGOID MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
TABLE 294. EGYPT BULLOUS PEMPHIGOID MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 295. EGYPT BULLOUS PEMPHIGOID MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 296. EGYPT BULLOUS PEMPHIGOID MARKET SIZE, BY ONLINE PHARMACY, 2018-2030 (USD MILLION)
TABLE 297. EGYPT BULLOUS PEMPHIGOID MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 298. EGYPT BULLOUS PEMPHIGOID MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 299. EGYPT BULLOUS PEMPHIGOID MARKET SIZE, BY SPECIALTY CLINICS, 2018-2030 (USD MILLION)
TABLE 300. EGYPT BULLOUS PEMPHIGOID MARKET SIZE, BY THERAPY LINE, 2018-2030 (USD MILLION)
TABLE 301. TURKEY BULLOUS PEMPHIGOID MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 302. TURKEY BULLOUS PEMPHIGOID MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 303. TURKEY BULLOUS PEMPHIGOID MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 304. TURKEY BULLOUS PEMPHIGOID MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
TABLE 305. TURKEY BULLOUS PEMPHIGOID MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 306. TURKEY BULLOUS PEMPHIGOID MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 307. TURKEY BULLOUS PEMPHIGOID MARKET SIZE, BY ONLINE PHARMACY, 2018-2030 (USD MILLION)
TABLE 308. TURKEY BULLOUS PEMPHIGOID MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 309. TURKEY BULLOUS PEMPHIGOID MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 310. TURKEY BULLOUS PEMPHIGOID MARKET SIZE, BY SPECIALTY CLINICS, 2018-2030 (USD MILLION)
TABLE 311. TURKEY BULLOUS PEMPHIGOID MARKET SIZE, BY THERAPY LINE, 2018-2030 (USD MILLION)
TABLE 312. ISRAEL BULLOUS PEMPHIGOID MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 313. ISRAEL BULLOUS PEMPHIGOID MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 314. ISRAEL BULLOUS PEMPHIGOID MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 315. ISRAEL BULLOUS PEMPHIGOID MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
TABLE 316. ISRAEL BULLOUS PEMPHIGOID MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 317. ISRAEL BULLOUS PEMPHIGOID MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 318. ISRAEL BULLOUS PEMPHIGOID MARKET SIZE, BY ONLINE PHARMACY, 2018-2030 (USD MILLION)
TABLE 319. ISRAEL BULLOUS PEMPHIGOID MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 320. ISRAEL BULLOUS PEMPHIGOID MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 321. ISRAEL BULLOUS PEMPHIGOID MARKET SIZE, BY SPECIALTY CLINICS, 2018-2030 (USD MILLION)
TABLE 322. ISRAEL BULLOUS PEMPHIGOID MARKET SIZE, BY THERAPY LINE, 2018-2030 (USD MILLION)
TABLE 323. NORWAY BULLOUS PEMPHIGOID MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 324. NORWAY BULLOUS PEMPHIGOID MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 325. NORWAY BULLOUS PEMPHIGOID MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 326. NORWAY BULLOUS PEMPHIGOID MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
TABLE 327. NORWAY BULLOUS PEMPHIGOID MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 328. NORWAY BULLOUS PEMPHIGOID MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 329. NORWAY BULLOUS PEMPHIGOID MARKET SIZE, BY ONLINE PHARMACY, 2018-2030 (USD MILLION)
TABLE 330. NORWAY BULLOUS PEMPHIGOID MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 331. NORWAY BULLOUS PEMPHIGOID MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 332. NORWAY BULLOUS PEMPHIGOID MARKET SIZE, BY SPECIALTY CLINICS, 2018-2030 (USD MILLION)
TABLE 333. NORWAY BULLOUS PEMPHIGOID MARKET SIZE, BY THERAPY LINE, 2018-2030 (USD MILLION)
TABLE 334. POLAND BULLOUS PEMPHIGOID MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 335. POLAND BULLOUS PEMPHIGOID MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 336. POLAND BULLOUS PEMPHIGOID MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 337. POLAND BULLOUS PEMPHIGOID MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
TABLE 338. POLAND BULLOUS PEMPHIGOID MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 339. POLAND BULLOUS PEMPHIGOID MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 340. POLAND BULLOUS PEMPHIGOID MARKET SIZE, BY ONLINE PHARMACY, 2018-2030 (USD MILLION)
TABLE 341. POLAND BULLOUS PEMPHIGOID MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 342. POLAND BULLOUS PEMPHIGOID MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 343. POLA

Samples

Loading
LOADING...

Companies Mentioned

The companies profiled in this Bullous pemphigoid market report include:
  • F. Hoffmann-La Roche AG
  • Sanofi S.A.
  • Argenx SE
  • Regeneron Pharmaceuticals, Inc.
  • GlaxoSmithKline plc
  • AstraZeneca plc
  • Novartis AG
  • AbbVie Inc.
  • Pfizer Inc.
  • Bristol-Myers Squibb Company

Table Information

Report AttributeDetails
No. of Pages185
PublishedMay 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 379.75 Million
Forecasted Market Value ( USD ) by 2030 $ 505.98 Million
Compound Annual Growth Rate5.9%
Regions CoveredGlobal
No. of Companies Mentioned11

Related Topics

Related Reports

Interleukin 13 Inhibitors - Pipeline Insight, 2025 - Product Image

Interleukin 13 Inhibitors - Pipeline Insight, 2025

  • Drug Pipelines
  • 60 Pages
  • Global
From
Pemphigus Vulgaris (PV) - Market Insight, Epidemiology and Market Forecast - 2034 - Product Image

Pemphigus Vulgaris (PV) - Market Insight, Epidemiology and Market Forecast - 2034

  • Report
  • 97 Pages
  • Global
From
Anterior Uveitis Treatment Market by Treatment Type, Drug Class, Route Of Administration, Distribution Channel, End User - Global Forecast to 2030 - Product Image

Anterior Uveitis Treatment Market by Treatment Type, Drug Class, Route Of Administration, Distribution Channel, End User - Global Forecast to 2030

  • Report
  • 192 Pages
  • Global
From
Crohn's Disease Therapeutics Market by Therapy Class, Route of Administration, Distribution Channel, End User - Global Forecast to 2030 - Product Image

Crohn's Disease Therapeutics Market by Therapy Class, Route of Administration, Distribution Channel, End User - Global Forecast to 2030

  • Report
  • 191 Pages
  • Global
From
Atopic Dermatitis Drugs Market Size, Share & Trends Analysis Report By Drug Class, By Route Of Administration, By Distribution Channel, By Region, And Segment Forecasts, 2025 - 2030 - Product Image

Atopic Dermatitis Drugs Market Size, Share & Trends Analysis Report By Drug Class, By Route Of Administration, By Distribution Channel, By Region, And Segment Forecasts, 2025 - 2030

  • Report
  • 120 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.